全文获取类型
收费全文 | 168048篇 |
免费 | 13629篇 |
国内免费 | 5275篇 |
专业分类
耳鼻咽喉 | 1176篇 |
儿科学 | 3273篇 |
妇产科学 | 1737篇 |
基础医学 | 24580篇 |
口腔科学 | 3192篇 |
临床医学 | 16922篇 |
内科学 | 24504篇 |
皮肤病学 | 1743篇 |
神经病学 | 8159篇 |
特种医学 | 3937篇 |
外国民族医学 | 22篇 |
外科学 | 14047篇 |
综合类 | 25311篇 |
现状与发展 | 11篇 |
一般理论 | 25篇 |
预防医学 | 12592篇 |
眼科学 | 4610篇 |
药学 | 17724篇 |
17篇 | |
中国医学 | 8135篇 |
肿瘤学 | 15235篇 |
出版年
2024年 | 358篇 |
2023年 | 2462篇 |
2022年 | 4954篇 |
2021年 | 6811篇 |
2020年 | 5829篇 |
2019年 | 6203篇 |
2018年 | 5932篇 |
2017年 | 5446篇 |
2016年 | 5329篇 |
2015年 | 5417篇 |
2014年 | 8846篇 |
2013年 | 9602篇 |
2012年 | 7869篇 |
2011年 | 9092篇 |
2010年 | 7877篇 |
2009年 | 7751篇 |
2008年 | 7852篇 |
2007年 | 8909篇 |
2006年 | 8053篇 |
2005年 | 8044篇 |
2004年 | 7013篇 |
2003年 | 6224篇 |
2002年 | 4606篇 |
2001年 | 4521篇 |
2000年 | 3698篇 |
1999年 | 3436篇 |
1998年 | 2447篇 |
1997年 | 2168篇 |
1996年 | 2289篇 |
1995年 | 2185篇 |
1994年 | 1913篇 |
1993年 | 1749篇 |
1992年 | 1518篇 |
1991年 | 1309篇 |
1990年 | 1106篇 |
1989年 | 1046篇 |
1988年 | 987篇 |
1987年 | 746篇 |
1986年 | 565篇 |
1985年 | 652篇 |
1984年 | 674篇 |
1983年 | 423篇 |
1982年 | 522篇 |
1981年 | 439篇 |
1980年 | 387篇 |
1979年 | 320篇 |
1978年 | 261篇 |
1977年 | 214篇 |
1976年 | 245篇 |
1975年 | 155篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
4.
5.
6.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
7.
8.
9.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献